Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders

European Journal of Haematology

Volumn 79, Issue SUPPL. 68, 2007, Pages 5-8

  Skoda, Radek ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Haematopoiesis; Janus kinase 2; Loss of heterozygosity; Mutation; Myeloproliferative disorders; Pathogenesis; Signal transducers and activators of transcription factors

Indexed keywords

ADAPTOR PROTEIN; CYTOKINE RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; RAS PROTEIN; STAT PROTEIN; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 9P; CONFERENCE PAPER; GENE DUPLICATION; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HETEROZYGOSITY LOSS; HUMAN; KNOCKOUT MOUSE; MICROSATELLITE MARKER; MITOTIC RECOMBINATION; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; THROMBOCYTHEMIA; ANIMAL; GENETICS; METABOLISM; MUTATION; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

EID: 34548259860     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00935.x     Document Type: Conference Paper

References (30)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434 : 1144 8.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 7 : 387 97.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005 365 : 1054 61.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005 352 : 1779 90.
5. Ihle JN, Kerr IM. Jaks and stats in signaling by the cytokine receptor superfamily. Trends Genet 1995 11 : 69 74.
6. Ihle JN. Cytokine receptor signalling. Nature 1995 377 : 591 4.
7. Khwaja A. The role of janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006 134 : 366 84.
8. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 2005 280 : 27251 61.
9. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001 8 : 1327 38.
10. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995 13 : 369 98.
11. Mnjoyan Z, Yoon D, Li J, Delhommeau F, Afshar-Karghan V. The effect of the JAK2 V617F mutation on PRV-1 expression. Haematologica 2006 91 : 411 2.
12. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006 355 : 2452 66.
13. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998 93 : 397 409.
14. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998 93 : 385 95.
15. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002 30 : 229 36.
16. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, Skoda RC. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003 102 : 1869 71.
17. Kratz CP, Boll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006 20 : 381 3.
18. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006 25 : 1434 6.
19. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000 20 : 3387 95.
20. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001 14 : 27 37.
21. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005 105 : 4187 90.
22. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007 356 : 459 68.
23. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006 108 : 1377 80.
24. Vannuchhi AM, Barosi G, Rambaldi A, Marchioli R, Barbui T, for the GIMEMA MPD WP. Clinical significance of JAK2 V617F homozygosity in the chronic myeloprofilerative disorders. A study on 1306 patients. Blood 2006 108 : 664.
25. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005 106 : 2162 8.
26. Tiedt R, Hao-Shen H, Skoda RC. A transgenic mouse model to study JAK2-V617F in vivo. Blood 2007 108 : 665.
27. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006 20 : 971 8.
28. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849 G>T is rare in acute leukemias but can be found in CMML, philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005 106 : 3370 3.
29. Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, Parvis G, Saglio G, Gaidano G, Cilloni D. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2006 135 : 267 8.
30. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC. Leukemic blasts in transformed JAK2-V617 F positive myeloproliferative disorders are frequently negative for the JAK2-V617 F mutation. Blood 2007 110 : 375 9.